Prevention of nephropathy in patients with type 2 diabetes mellitus

International Urology and Nephrology

Volumn 37, Issue 3, 2005, Pages 655-663

  Tzamaloukas, Antonios H ^a   Murata, Glen H ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy prevention; Glycemia; Hypertension; Lipid metabolism; Nephrotoxins; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASTAXANTHIN; BERAPROST; BOSENTAN; CERIVASTATIN; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EBSELEN; EPALRESTAT; ESTRADIOL; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; OCTREOTIDE; OMAPATRILAT; OSTEOGENIC PROTEIN 1; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PYRIDOXAMINE; RUBOXISTAURIN; SARPOGRELATE; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; THIOCTIC ACID; UNINDEXED DRUG;

ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; DIABETIC NEPHROPATHY; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; HEREDITY; HUMAN; HYPERTENSION; INCIDENCE; LIPID BLOOD LEVEL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PHOSPHATE METABOLISM; PROTEIN DIET; RISK FACTOR; SMOKING CESSATION;

ALBUMINURIA; ANEMIA; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ERYTHROPOIETIN; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MITOCHONDRIA;

EID: 28844433606     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-005-2394-3     Document Type: Article

References (40)

1. PA Kiberstis 2005 A surfeit of subjects Science 307 36910.1126/ science.307.5708.369 1:CAS:528:DC%2BD2MXmvVehuw%3D%3D
2. HH Parving M Mauer E Ritz 2004 Diabetic nephropathy In: BM Brenner (ed.) The Kidney 7 Saunders Philadelphia, PA 1177-1818
3. J Tuomilheto J Lindstrom HG Eriksson 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 1343-1350
4. WC Knowler E Barrett-Connor SE Fowler 2002 Reduction in the incidence of type 2 diabetes with lifestyle interventions or metformin N Engl J Med 346 393-403 1:CAS:528:DC%2BD38XhtVWqurc%3D
5. S O'Rahilly I Barroso NJ Wareham 2005 Genetic factors in type 2 diabetes: The end of the beginning? Science 307 370-373 1:CAS:528:DC%2BD2MXksFyhsw%3D%3D
6. P Paulsen G Andersen M Genger 2003 Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: Thrifty genotype, thrifty phenotype, or both? Diabetes 52 194-198
7. T Kadowaki K Hara T Yamauchi 2003 Molecular mechanism of insulin resistance and obesity Exp Biol Med (Maywood) 228 1111-1117 1:CAS:528:DC%2BD3sXptFWnurs%3D
8. J Vander Molen LM Frisse SM Fullerton 2004 Population genetics of CAPN10 and GPR35: Implications for the evolution of type 2 diabetes variants Diabetes 53 3274-3285
9. MA Lazar 2005 How obesity causes diabetes: Not a tall tale Science 307 373-375 10.1126/science.1104342 1:CAS:528:DC%2BD2MXksFyhsA%3D%3D
10. MW Schwartz D Porte Jr 2005 Diabetes, obesity and the brain Science 307 375-379 10.1126/science.1104344 1:CAS:528:DC%2BD2MXksFyhsQ%3D%3D
11. SE Kahn 2001 The importance of β-cell failure in the development and progression of type-2 diabetes J Clin Endocrinol Metab 86 4047-4058 1:CAS:528:DC%2BD3MXmvFCktrY%3D
12. CJ Rhodes 2005 Type 2 diabetes - a matter of β-cell life and death? Science 307 380-384 10.1126/science.1104345 1:CAS:528:DC%2BD2MXksFyhtg%3D%3D
13. BB Lowelll GI Shulman 2005 Mitochodrial dysfunction and type 2 diabetes Science 307 384-387
14. P Fioretto MW Steffes DER Sutherland 2998 Reversal of lesions of diabetic nephropathy after pancreas transplantation N Engl J Med 339 69-75
15. J Pirart 1978 Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 Diabetes Care 1 168-188
16. KF Hanssen K Dahl-Jorgensen T Lauritzen 1986 Diabetic control and microvascular complications Diabetologia 29 677-684 10.1007/BF00870275 1:STN:280:BiiC3cnksVY%3D
17. Y Ohkubo H Kishikawa E Araki 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study Diab Res Clin Pract 28 103-117 10.1016/0168-8227(95)01064-K 1:CAS:528:DyaK2MXpsVWgtrs%3D
18. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
19. K Zandi-Nejad BM Brenner 2005 Strategies for renoprotection: 2005 Nephrol Rounds (Brigham and Women's Hospital) 3 2 1-5
20. BL Kassiske R Kalil JZ Ma 1993 Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis Ann Intern Med 118 129-138
21. M Ravid D Brosh Z Levi et al. 1998 Use of enalapril to attenuate decline in renal function in normotensive, microalbuminuric patients with type 2 diabetes mellitus Ann Intern Med 128 982-988 1:CAS:528:DyaK1cXktF2mtbw%3D
22. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy Lancet 355 253-259
23. P Tatti M Pahor RP Byington et al. 1998 Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 597-603 1:STN:280:DyaK1c3jt1ynsg%3D%3D
24. UK Prospective Diabetes Study (UKPDS) Group 1998 Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39 BMJ 317 713-720
25. RO Estasio BW Jeffers N Gifford RW Schrier 2000 Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 (Suppl. 2) B54-B64
26. RW Schrier RO Estasio A Esler P Mehler 2002 Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 1086-1097 10.1046/ j.1523-1755.2002.00213.x
27. AR Andersen JT Christiansen JK Andersen et al. 1983 Diabetic nephropathy in type 1 (insulin dependent) diabetes: An epidemiological study Diabetologia 25 496-501 10.1007/BF00284458 1:STN:280:BiuC3cbivFI%3D
28. G Norden G Nyberg 1984 Smoking and diabetic nephropathy Acta Med Scand 215 257-261 1:STN:280:BiuB38jks1M%3D
29. HP Hansen E Tauber-Lassen BR Jensen HH Parving 2002 Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy Kidney Int 62 220-228 10.1046/j.1523-1755.2002.00421.x
30. P Gaede P Vedel HH Parving O Pedersen 1999 Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomized study Lancet 353 617-622 1:STN:280:DyaK1M7ltleqtQ%3D%3D
31. EJ Lewis LG Hunsicker RO Bain RD Rohde 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1456-1462 1:STN:280:ByuD3MbmtFM%3D
32. EJ Lewis LG Hunsicker WR Clarke et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes N Engl J Med 35 851-860
33. BM Brenner ME Cooper D Zeeuw de et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D
34. HH Parving H Lehnert J Brochner-Mortensen et al. 2001 The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878 10.1056/NEJMoa011489 1:CAS:528:DC%2BD3MXntlelsLY%3D
35. G Viberti NM Wheeldon 2002 Microalbuminuria reduction in patients with type 2 diabetes mellitus: A blood-pressure independent effect Circulation 106 672-678 10.1161/01.CIR.0000024416.33113.0A 1:CAS:528:DC%2BD38XmvFSmsL8%3D
36. CE Mogensen S Neldam I Tikkanen et al. 2000 Randomized controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study BMJ 3 21 1440-1444
37. N Nakao A Yoshimura H Morita et al. 2003 Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial Lancet 361 117-124 1:CAS:528:DC%2BD3sXisl2rtQ%3D%3D
38. GM Chertow SK Burke P Raggi 2002 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 245-252 10.1046/j.1523-1755.2002.00434.x 1:CAS:528:DC%2BD38XlsFyqu74%3D
39. K Lau 1989 Phosphate excess and progressive renal failure: The precipitation-calcification hypothesis Kidney Int 36 918-937 1:STN:280:By%2BC3svnt1Y%3D
40. C Gouva P Nikolopoulos JPA Ioannidis KC Siamopoulos 2004 Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial Kidney Int 66 753-760 10.1111/ j.1523-1755.2004.00797.x